tissues. This ability makes their complete surgical resection difficult and focal therapy ineffective. Cerebrospinal fluid dissemination by tumor cells is an important factor for the determination of the poor prognosis in patients with glioblastomas multiforme. Thus, understanding the mechanisms of astrocytic tumor cell invasion of the brain and CSF dissemination is essential to the development of new strategies to control malignant astrocytomas. Glioma invasion involves cell adhesion and proteolytic degradation of ECM, 8 and a positive correlation between tumor malignancy and the production of MMPs, especially MMP-2, has been reported in astrocytic tumors. 5, 24, 36, 41 The results of previous studies have also shown that the expression levels of MT1-MMP correlate with the degree of proMMP-2 activation, 17, 23, 42 and that both TIMP-1 and TIMP-2 are detectable in human malignant astrocytic tumor tissues. 24, 27 However, in these studies the investigators did not measure the production levels of TIMPs or examine their role in the invasion of astrocytic tumors. In addition, little is known about the relationship between the CSF dissemination and the expression of these MMPs and TIMPs in astrocytic tumors.
In the present study, we examined the production levels and tissue localization of MMP-2, MT1-MMP, TIMP-1, and TIMP-2, and analyzed correlations between them and histological grades and CSF dissemination in astrocytic tumors in humans. In addition, we experimentally studied the roles of these molecules in the invasion of collagen gels by using MT1-MMP transfectants of a U251 glioblastoma cell line. The results indicated that an imbalance between MT1-MMP and TIMP-2 plays a key role in the invasion and CSF dissemination of malignant astrocytic tumors.
Materials and Methods

Clinical Samples and Histological Investigation
Fresh brain tumor tissue samples were obtained at the time of resection from 49 patients with astrocytic tumors and 10 patients with lung adenocarcinomas that had metastasized to the brain. Normal brain tissues were obtained at the time of surgery from eight patients who had undergone temporal lobectomy for epilepsy. The samples were snap-frozen in liquid nitrogen immediately after surgical removal, and stored at Ϫ80˚C to extract total RNA and proteins. The tissue samples were also fixed with periodate-lysine-paraformaldehyde or 4% paraformaldehyde fixative for 18 to 24 hours at 4˚C for immunohistochemical study. Histological diagnosis was based on findings of standard light microscopy evaluation of sections stained with hematoxylin and eosin. The classification of human brain tumors used in this study is based on the revised World Health Organization criteria for tumors of the central nervous system. 15 A total of 49 astrocytic tumors consisted of eight low-grade astrocytomas, 11 anaplastic astrocytomas, and 30 glioblastomas multiforme. All tumor tissues were obtained during primary resection and none of the patients had undergone chemotherapy or radiation therapy before resection. Among 49 patients with astrocytic tumors, six patients with glioblastoma were found to have CSF dissemination of tumor during their hospital stay, based on findings on magnetic resonance images.
Tissue Homogenates and Sandwich EIAs for proMMP-2, TIMP-1, and TIMP-2
Tissue samples of brain tumors (49 samples of primary astrocytic tumor and 10 samples of tumor that had metastasized to the brain) and healthy brains (eight samples) were homogenized in 50 mM Tris-HCl buffer (pH 7.5) containing 0.15 M NaCl, 10 mM CaCl 2 , and 0.05% Brij35 on ice. The homogenates were centrifuged at 4˚C for 20 minutes at 10,000 G, and protein concentrations in the supernatants were determined by using dye-binding methods according to the manufacturer's instructions. Concentrations of proMMP-2, TIMP-1, and TIMP-2 in the tissue homogenates were measured using appropriate sandwich EIA systems, as described previously. 6, 7, 16 The EIA for MMP-2 is used to measure proMMP-2 and its complex form with TIMP-2, but not active MMP-2 species. 6 The EIA for TIMP-1 is used to determine the entire amount of TIMP-1, including free TIMP-1 and complex forms with active MMPs and proMMP-9. 16 On the other hand, the EIA for TIMP-2 detects both free TIMP-2 and the TIMP-2 that is complexed with active MMPs, but not the TIMP-2 that is complexed with proMMP-2. 7 Values were expressed as nanomoles per gram of protein. The following molecular weights derived from the amino acid sequences were used for calculation: 70,930 for proMMP-2, 20,695 for TIMP-1, and 21,740 for TIMP-2. 26 
Quantitative RT-PCR
The total RNA that was extracted was treated with RNase-free DNase to eliminate DNA contamination in the samples, and was then converted to single-strand cDNA by using a random hexamer of oligonucleotides. Randomly primed cDNAs were prepared from 5 µg total RNA by using Moloney murine leukemia virus reverse transcriptase followed by PCR amplification. Nonradioisotopic quantitative RT-PCR was performed as previously described. 21, 22 Amplification of cDNAs obtained from surgical specimens was accomplished using specific primers of human MT1-MMP (forward primer 5Ј-TCGGCCCAAAGCAGCAGCTTC-3Ј, reverse primer 5Ј-CTTCATGGTGTCTGCATCAGC-3Ј) and GAPDH (forward primer 5Ј-CCACCCATGGCAAATTCCATGGCA-3Ј, reverse primer 5Ј-TCTAGACGGCAGGTCAGGTCCACC-3Ј), which amplified 180-bp and 598-bp fragments, respectively. 21 The PCR conditions for MT1-MMP amplifications were 20 to 36 cycles at two-cycle intervals at 94˚C for 1 minute, 50˚C for 1 minute, and 72˚C for 1 minute, followed by incubation at 72˚C for 3 minutes. The conditions for GAPDH amplifications were the same as those for MT1-MMP amplification, except there was 1 minute of annealing at 60˚C. The products were electrophoresed on 2% agarose gels, including 0.1 µg/ml ethidium bromide. The intensity of the ethidium bromide-induced fluorescence was measured using a chargecoupled device imaging system and digital imaging film. The reaction cycle and the PCR products of each reaction mixture were plotted on semilogarithmic graphs. To standardize the condition of gel staining, a constant amount of control DNA marker was electrophoresed every time. The PCR procedure was performed at least three times for each sample. When RT-PCRs for MT1-MMP and GAPDH were performed using total RNA from glioblastomas by running 20 to 36 cycles at intervals of two cycles, the products emerged between 22 and 26 cycles, increased exponentially up to 30 to 34 cycles, and then reached a plateau (data not shown). Thus, PCR amplification was set at 28 cycles. The fluorescence intensity of each PCR product was measured, and MT1-MMP/GAPDH ratios of surgical specimens were calculated. We analyzed each sample at least three times by using this method, and the difference between the values we obtained was less than 2%.
Immunohistochemical Analysis
Paraffin-embedded sections of tissue were immunostained using monoclonal antibodies to TIMP-1 (10 µg/ml; Clone 147-6D11), TIMP-2 (2 µg/ml; Clone 67-4H11), MT1-MMP (30 µg/ml; Clone 114-6G6), or nonimmune mouse IgG (10 µg/ml). After tissue reactions had been achieved by using biotinylated horse IgG to mouse IgG and an avidin-biotin-peroxidase complex, the color was developed using 3,3Ј-diaminobenzidine tetrahydrochloride. Counterstaining was performed using hematoxylin.
Cell Cultures and MT1-MMP Transfection
The U251 human glioblastoma cell line 2 was maintained in Dulbecco's modified Eagle's medium, which was supplemented with 10% fetal bovine serum. The expression plasmid for MT1-MMP was constructed by inserting a full-length MT1-MMP cDNA (3.4 kb) 35 at the multicloning site of the pCEP4 plasmid, which contains the hygromycin B-resistant gene and was transfected into U251 cells by using the calcium phosphate method. 34 Stable transfectants of MT1-MMP were established by culturing them in the presence of 200 µg/ml hygromycin B. Inhibition of proMMP-2 activation by TIMP-1 or TIMP-2 was examined by addition of these human recombinant TIMPs to the culture media at a final concentration of 5 µg/ml.
Extraction of RNA and Northern Blot Analysis
Total RNA was isolated from the cells by using an RNA extraction mixture. To confirm the transfection, Northern blot analysis was performed. The RNA samples (10 µg/lane) were electrophoresed on 1% agarose gels containing 2.2 M formaldehyde and transferred onto Hybond N ϩ membranes. The membranes were hybridized using 32 P-labeled probes for MT1-MMP (a 1.2-kb cDNA fragment corresponding to nucleotides 1647-2889) and GAPDH, as previously described. 35 
Immunoblot Analysis
Cells were solubilized using SDS-PAGE sample buffer with the aid of sonication, electrophoresed on 10% SDS-PAGE, and transferred onto nitrocellulose filters. The filters were reacted with 20 µg/ml monoclonal antibodies to MT1-MMP (Clone 114-1F2). After tissue reactions had been achieved using biotinylated horse IgG to mouse IgG and an avidin-biotin-peroxidase complex, the color was developed using 3,3Ј-diaminobenzidine tetrahydrochloride, as described previously. 29 
Gelatin Zymography
The extent of gelatinolytic activity in tissue homogenates of glioblastomas multiforme and in culture media was examined using gelatin zymography. The homogenates (50 µg/lane) and culture media (20 µl/lane) were subjected to SDS-PAGE in which 0.2% gelatincontaining gels were used in a manner described previously. 21 The samples were incubated at 37˚C for 30 minutes in SDS sample buffer without reducing agent, and then electrophoresed on 9% polyacrylamide gels at 4˚C. After electrophoresis, the gels were washed in 2.5% Triton-X 100 to remove the SDS; incubated for 12 hours at 37˚C in 50 mM Tris-HCl (pH 7.5) containing 0.15 M NaCl, 10 mM CaCl 2 , and 0.02% NaN 3 ; and then stained with 0.1% Coomassie brilliant blue R250. The proMMP-2 activation ratios were measured with the aid of computer-assisted image analysis, as described previously. 21 
Degradation of Gelatin
Cells were seeded at 10 6 cells/35-mm plastic dish in Dulbeco's modified Eagle's medium supplemented by fetal bovine serum. Following an overnight incubation, the medium in the dishes was replaced with 0.4 ml of 50 mM Tris-HCl buffer (pH 7.5) containing 0.15 M NaCl, 10 mM CaCl 2 , and 50 µg/ml gelatin; and the cells were incubated for 5 hours at 37˚C. Human recombinant TIMP-1 or TIMP-2 was added to the digestion buffer at a final concentration of 5 µg/ml in some dishes. The digestion products were analyzed in 7% SDS-PAGE under reduction. The proMMP-2 activation ratio was also analyzed using gelatin zymography, as described earlier in this paper.
Three-Dimensional Cultures in Type I Collagen Gel
Type I collagen gel for 3D cell cultures was prepared according to the manufacturer's instructions and the cells were plated within the gel. Recombinant TIMP-1 or TIMP-2 was added to the medium at a final concentration of 5 µg/ml in some cell cultures.
Statistical Analysis
Statistical analyses were performed using the chi-square test and the two-tailed Mann-Whitney U-test. Probability values lower than 0.05 were considered significant. In this paper values for groups are expressed as the means Ϯ standard deviation.
Sources of Supplies and Equipment
The human recombinant TIMPs were graciously provided by Dr. Kazushi Iwata of Fuji Chemical Industries, Ltd. (Takaoka, Japan). The U251 human glioblastoma cell line was obtained from American Type Culture Collection (Rockville, MD).
BioRad (Hercules, CA) provided the dye-binding materials used to determine protein concentration of supernatants and the instructions for their use. The RNAse-free DNAse was acquired from Boehringer Mannheim (Mannheim, Germany) and the random hexamer of oligonucleotides from Takara (Otsu, Japan). The Moloney murine leukemia virus reverse transcriptase was purchased from Gibco BRL (Gaithersburg, MD) and the control DNA marker from Promega (Madison, WI). The biotinylated horse IgG and biotinylated mouse IgG were acquired from Vector Laboratories (Burlingame, CA), the avidin-biotin-peroxidase complex was obtained from Dako Corp. (Glostrup, Denmark), and the 3,3Ј-diaminobenzidine tetrahydrochloride from Sigma Chemical Co. (St. Louis, MO). The pCEP4 plasmid was purchased from Invitrogen (Groningen, The Netherlands), the Isogen RNA extraction mixture from Nippon Gene (Toyama, Japan), the Hybond N ϩ membranes from Amersham International (Tokyo, Japan), and the nitrocellulose filters from Amersham International (Buckinghamshire, United Kingdom). The Type I collagen gel was obtained from Nitta Gelatin (Osaka, Japan).
The FAS II charge-coupled device imaging system was manufactured by Toyobo (Tokyo, Japan) and the Digital Image File Fujix DF-20 film by Fuji Photo Film (Tokyo, Japan).
Results
Results of Sandwich EIAs for ProMMP-2, TIMP-1, TIMP-2, and ProMMP-2 Activation
To measure the amounts of proMMP-2, TIMP-1, and TIMP-2 produced by tumor tissues, EIAs were applied to supernatants of tissue homogenates. As shown in Fig. 1 , the production levels of proMMP-2 in the samples of glioblastoma (0.041 Ϯ 0.026 nmol/g protein, 30 samples) were remarkably higher than those measured in samples of anaplastic astrocytoma (0.019 Ϯ 0.008, p Ͻ 0.01, 11
FIG. 1. Graph depicting the amounts of proMMP-2 in tissue homogenates of astrocytic tumors, metastatic brain tumors, and normal brain tissue. The supernatants from tissue samples of normal brain (NB), low-grade astrocytoma (LGA), anaplastic astrocytoma (AA), glioblastoma (GB), and tumor that has metastasized to the brain (Meta) were prepared, and proMMP-2 was measured using EIA. Values (nmol/g protein) were calculated in the manner described in Materials and Methods. Bars indicate mean values. n = number of tissue samples: *p Ͻ 0.05; **p Ͻ 0.01. samples), low-grade astrocytoma (0.014 Ϯ 0.008, p Ͻ 0.01, eight samples), control healthy brain tissue (0.007 Ϯ 0.003, p Ͻ 0.01, eight samples), or tumor that had metastasized to the brain (0.015 Ϯ 0.006, p Ͻ 0.01, 10 samples). The production levels of TIMP-1 in samples of glioblastoma (0.388 Ϯ 0.266 nmol/g protein, 30 samples) and samples of tumor that had metastasized to the brain (0.731 Ϯ 0.5, 10 samples) were also remarkably higher than those measured in samples of anaplastic astrocytoma (0.088 Ϯ 0.077, p Ͻ 0.01, 11 samples), low-grade astrocytoma (0.024 Ϯ 0.019, p Ͻ 0.01, eight samples), and control healthy brain tissue (0.021 Ϯ 0.013, p Ͻ 0.01, eight samples; Fig. 2) . No difference in production levels of TIMP-2 could be observed among samples of glioblastoma (0.307 Ϯ 0.156 nmol/g protein, 30 samples), anaplastic astrocytoma (0.29 Ϯ 0.134, 11 samples), lowgrade astrocytoma (0.19 Ϯ 0.099, eight samples), and normal brain tissue (0.262 Ϯ 0.118, eight samples; Fig. 2) . However, the level of TIMP-2 in samples of tumor that had metastasized to brain (0.107 Ϯ 0.067, 10 samples) was remarkably lower compared with levels in samples of primary brain tumors and healthy brain tissue (p Ͻ 0.01; Fig. 2 ).
When the production levels of these molecules were compared between glioblastomas associated with and without CSF dissemination, the TIMP-2 level was significantly lower in those samples of tumors associated with CSF dissemination (0.134 Ϯ 0.038 nmol/g protein, six samples) than in those samples not associated with dissemination (0.35 Ϯ 0.143, p Ͻ 0.01, 24 samples; Fig.  3C ). However, no difference in levels of proMMP-2 and TIMP-1 was demonstrated between glioblastomas associated with CSF dissemination (0.044 Ϯ 0.029 and 0.459 Ϯ 0.33 nmol/g protein, respectively; six samples) and those not associated with CSF dissemination (0.04 Ϯ 0.25 and 0.37 Ϯ 0.253, respectively; 24 samples) ( Fig. 3A and B) . On the other hand, although the results of gelatin zymography showed that both proMMP-2 (68 kD) and active MMP-2 (62 kD) were present in all glioblastoma samples, the proMMP-2 activation ratio (active MMP-2/[proMMP-2 ϩ active MMP-2]) was remarkably higher in glioblastomas associated with CSF dissemination (21.0 Ϯ 4.8%, six samples) than in those not associated with CSF dissemination (11.8 Ϯ 6.6%, p Ͻ 0.01, 24 samples; Fig. 3D ).
Messenger RNA Expression of MT1-MMP
The MT1-MMP mRNA was expressed in 100% of the glioblastomas (30 of 30 samples) and the lung adenocarcinomas that had metastasized to the brain (10 of 10 samples). It was only detectable in 27% of the anaplastic astrocytomas (three of 11 samples) and was undetectable in low-grade astrocytomas (zero of eight samples) or normal brain tissue (zero of eight samples). The results of the quantitative RT-PCR indicated that levels of MT1-MMP/ GAPDH ratios were significantly higher in glioblastomas (0.45 Ϯ 0.28, 30 samples) than in anaplastic astrocytomas (0.07 Ϯ 0.15, p Ͻ 0.05, 11 samples), low-grade astrocytomas (zero, p Ͻ 0.01, eight samples), or normal brain tissues (zero, p Ͻ 0.01, eight samples) (data not shown). In addition, the expression level of MT1-MMP was remarkably higher in glioblastomas that were associated with CSF dissemination (0.78 Ϯ 0.26, six samples) than in those not associated with dissemination (0.37 Ϯ 0.21, p Ͻ 0.01, 24 samples; Fig. 3E ).
Immunohistochemical Findings
The TIMP-1 was predominantly immunolocalized to neoplastic astrocytes in all glioblastomas (30 of 30 samples; Fig. 4A ) and to tumor cells in all cases of lung ade-
J. Neurosurg. / Volume 94 / March, 2001
Roles of MT1-MMP and TIMP-2 in human glioma invasion 467 FIG. 2. Graphs demonstrating the amounts of TIMP-1 and TIMP-2 in tissue homogenates of astrocytic tumors, metastatic brain tumors, and normal brain tissue. The supernatants from tissue samples of normal brain, low-grade astrocytoma, anaplastic astrocytoma, glioblastoma, and tumor that had metastasized to the brain were prepared, and TIMP-1 and TIMP-2 were measured using appropriate EIA. Bars indicate mean values. *p Ͻ 0.05; **p Ͻ 0.01. nocarcinomas that had metastasized to the brain (10 of 10 samples; data not shown). In anaplastic astrocytomas, some atypical cells were weakly immunostained, but no definite staining was seen in normal brain tissues or in low-grade astrocytomas (data not shown). The TIMP-2 also was predominantly immunostained in neoplastic astrocytes in the glioblastomas (30 of 30 samples; Fig. 4B ). In normal brain tissues, astrocytes were immunostained, but only some tumor cells were weakly immunostained in tumors that had metastasized to the brain (data not shown). Like TIMPs, MT1-MMP also was predominantly immunolocalized to neoplastic astrocytes in all glioblastomas (30 of 30 samples; Fig. 4C ). In anaplastic astrocytomas and tumors that had metastasized to the brain, some atypical cells were weakly immunostained, but no staining was observed in normal brain tissues or in lowgrade astrocytomas (data not shown). The endothelial cells of blood vessels within tumor tissues were occasionally immunostained for TIMP-1, TIMP-2, and MT1-MMP. No staining was observed in response to nonimmune mouse IgG (Fig. 4D) .
Activation of ProMMP-2 in U251 Cells Transfected With MT1-MMP
To analyze the role of these molecules in the invasion of astrocytic tumors, MT1-MMP was expressed in U251 cells. Two clones of U251 cells transfected with the MT1-MMP gene were selected. Northern blot and immunoblot analyses indicated that MT1-MMP is not expressed in parental U251 cells or in mock transfectants ( Fig. 5A and B) . Both MT1-MMP transfectants (MT1a and MT1b) synthesized 3.4-kb mRNA and 58-kD protein for MT1-MMP ( Fig. 5A and B ). All these cells produced 68 kD proMMP-FIG. 3. Graphs demonstrating the correlation of proMMP-2, TIMP-1, and TIMP-2 production, the proMMP-2 activation, ratio, and MT1-MMP expression with CSF dissemination. Production levels of proMMP-2 (A), TIMP-1 (B), and TIMP-2 (C), and the proMMP-2 activation ratio (D) in glioblastomas that were (ϩ) or were not (Ϫ) associated with CSF dissemination were compared. The MT1-MMP mRNA levels (E) in glioblastomas that were or were not associated with CSF dissemination were compared after standardization with levels of GAPDH, as described in Materials and Methods. The highest level of MT1-MMP mRNA expression is 1. Bars indicate mean values. NS = not significant; **p Ͻ 0.01. 2 in the culture medium (Fig. 5C) ; however, the active 62-kD MMP-2 species was found only in medium from MT1-MMP stable transfectants. It was absent in parental cells and in mock transfectants (Fig. 5C ). The degree of MMP-2 activation was considerably higher in MT1a, which expresses MT1-MMP at a higher level than MT1b. The proMMP-2 activation in MT1-MMP transfectants was inhibited by the presence of TIMP-2, but not TIMP-1 (Fig. 5C ).
Degradation of Gelatin by MT1-MMP Transfectants
To examine whether MT1-MMP expression correlates with proteolytic activity, parental U251 cells, mock transfectants, or MT1-MMP stable transfectants were incubated with gelatin and the resulting digestion products were analyzed using SDS-PAGE. As shown in Fig. 6 , the gelatin was efficiently digested by MT1-MMP transfectants (data not shown for MT1b), and the degradation was completely inhibited by addition of recombinant TIMP-2, but not TIMP-1, to the media. Parental U251 cells and mock transfectants did not digest the gelatin (Fig. 6 ).
Invasive Growth by MT1-MMP Transfectants
The U251 cells and those transfected with control or MT1-MMP expression plasmid were examined for their growth on plastic dishes and in 3D collagen gel. Parental cells and mock transfectants exhibited a spindle-shaped structure on plastic dishes, and cells expressing MT1-MMP were morphologically indistinguishable from the parent cells (data not shown). These cells grew with comparable doubling times (data not shown). In 3D collagen gel cultures, parental U251 cells and mock transfectants grew in an attached cell-to-cell form ( Fig. 7A and B , respectively). In contrast, an examination of MT1-MMP stable transfectants demonstrated more scattered growth in the collagen gel ( Fig. 7C for MT1a; data not shown for MT1b). Scattering of MT1a cells was specifically inhibited by addition of recombinant TIMP-2 ( Fig. 7E ), but not TIMP-1 (Fig. 7D) .
Discussion
In the present study we have shown that production levels of proMMP-2 are significantly enhanced as tumor grade increases from low-grade astrocytomas to glioblastomas multiforme. This confirms data described in previous reports including our own. 17, 21, 24, 36, 41, 42 However, the results of the present study demonstrate that TIMP-1 levels are higher as tumor grade increases, whereas TIMP-2 is constitutively produced regardless of tumor grade. Our findings on TIMP-2 are different from those of a recent report 12 in which lower levels of TIMP-2 were found to correlate with increasing glioma grade. This discrepancy may have arisen from the different assays used (sandwich EIA in the present study compared with semiquantitative immunoblot analysis in the work performed by Kachra and colleagues 12 ). Because the results of our previous studies, in which the same sandwich EIA systems were used, indicated that TIMP-1, but not TIMP-2, is commonly overproduced in human carcinomas of stomach, 28 thyroid, 26 endometrium, 40 and oral mucosa; 38 the production profile of these TIMPs appears to be common to malignant tumors. Originally TIMP-1 was reported to be a general inhibitor of MMPs, 9 but recent studies have disclosed that it has growth-promoting activity 11 and antiapoptotic effects. 19 It is not clear at present what is the major function of TIMP-1 in malignant tumors including glioblastomas. On the other hand, experimental studies including the present one have provided evidence that TIMP-2 inhibits glioma cell migration and invasion, 1, 3, 4 indicating the involvement of TIMP-2 in the regulation of local MMP activity in tumor tissues. Actually, the results of the present study indicated that TIMP-2 levels are significantly lower in tumors that have metastasized to the brain (in this instance, lung adenocarcinomas) than in astrocytic tumors and normal brain tissues. This was also the case when levels of TIMP-2 were compared between glioblastomas associated with CSF dissemination and those not associated with dissemination. Therefore, it is feasible that TIMP-2 is a negative regulator for primary and metastatic brain tumors in humans.
The present study is the first in which the association of overexpression of MT1-MMP and low production of TIMP-2 has been demonstrated in glioblastomas associated with CSF dissemination. Because the activation of pro-MMP-2 by MT1-MMP is accelerated in the presence of an appropriate amount of TIMP-2 (Ͻ an equimolar TIMP-2/MT1-MMP ratio) but is inhibited by a larger amount of TIMP-2, 14 this combination seems to enhance proMMP-2 activation. In accordance with this consideration, the activation ratio was significantly higher in glioblastomas associated with CSF dissemination than in those not associated with dissemination. As production levels of pro-MMP-2 and TIMP-1 were similar in both glioma groups, glioblastoma cells associated with CSF dissemination may be able to exhibit more invasiveness under such conditions through the efficient proMMP-2 activation by MT1-MMP and the enzymatic activities of both MMPs. The CSF dissemination of glioma cells requires destruction of the barrier between the subarachnoid space and brain parenchyma, that is, the so-called glial limitans externa, which consists mainly of types I, III, and IV collagens. 33 The MT1-MMP digests types I and III collagens, and the degradation of this barrier is synergistically enhanced in the presence of active MMP-2. 30 On the other hand, our recent experiments revealed that brevican, which is a specific proteoglycan present as a major ECM component in adult brains, is degraded by MMP-2, but not MT1-MMP. 25 In addition, type IV collagen is digested by MMP-2, 32 but is resistant to MT1-MMP. 30 Thus, these findings indicate that the coexpression of MT1-MMP and MMP-2 activities appears to be important for the breakdown of the glial limitanse externa, whereas MMP-2 activity generated by MT1-MMP might be sufficient for the invasion of surrounding brain tissue by glioma cells.
The experimental data found in the present study demonstrated that the invasion of collagen gel by MT1-MMP stable transfectants is completely inhibited by addition of TIMP-2. In this experimental system, invasive growth was observed only with MT1-MMP transfectants. In addition, inhibition of the invasion was TIMP-2-specific, because no inhibition was seen with TIMP-1. Recent biochemical studies have indicated that TIMP-1 is not an inhibitor of MT1-MMP, although TIMP-2 and TIMP-3 can inhibit the activity in a 1:1 stoichiometric fashion. 37 Thus, these data indicate that MT1-MMP plays an essential role in invasion in the present experimental model by using the transfectants of glioma cells. Similar findings have been reported for tumor spheroid outgrowth assays and collagen lattice cultures. 3, 4 In the present study, however, we showed that stable transfection of MT1-MMP induces activation of proMMP-2, and gelatinolytic activity is detected by using the transfectants. Interestingly, gelatin digestion was inhibited by TIMP-2, but not by TIMP-1, and the inhibition was accompanied by the disappearance of proMMP-2 activation. On the basis of these data we can infer that TIMP-2 hampers the enzymatic actions of MT1-MMP and MMP-2, the latter of which was generated by MT1-MMP on the cell membranes. The finding that TIMP-1 could not inhibit the activity indicates the possibility that pericellular ECM digestion by the MMP-2/ TIMP-2/MT1-MMP system may not be blocked by the exogenous addition of TIMP-1, as proposed by Deryugina and colleagues. 3, 4 In any case, the present invasion model, in which type I collagen is used, may mimic conditions for the invasion of the glial limitanse externa by glioma cells, and the data provide supportive evidence that MT1-MMP plays an essential part in CSF dissemination through proMMP-2 activation and the enzymatic activities of both MMPs.
Hepatocyte growth factor, a pleiotropic factor that regulates cellular proliferation, differentiation, motility, and tumor progression, is reported to induce expression of MT1-MMP and MMP-2, together with suppression of TIMP-2 expression in human glioblastoma cell lines. 10 This HGF is expressed in human gliomas and its expression levels are higher in glioblastomas than in low-grade astrocytomas or healthy brain tissues. 18, 20 Furthermore, the results of our previous 21 and present studies on immunolocalization have shown that MT1-MMP, MMP-2, and TIMP-2 are all produced in glioblastoma cells in vivo. Thus, it seems likely that HGF stimulates glioma cells in a paracrine and/or autocrine manner to regulate expression levels of MT1-MMP, MMP-2, and TIMP-2 in tumor tissues.
Conclusions
In summary, we have demonstrated that overexpression of MT1-MMP and downregulation of TIMP-2 may contribute to CSF dissemination by human glioblastoma cells through enhanced activation of proMMP-2, which is mediated by MT1-MMP and the enzymatic activities of both MMPs. These data may provide an important clue for the development of a new therapy for human malignant astrocytic tumors.
